AlzChem Group（ACT）株式概要
アルツケムグループAGは、その子会社とともに、ドイツ、欧州連合、その他の欧州諸国、アジア、NAFTA地域、および国際的に、さまざまな化学特殊製品を開発、生産、販売している。 詳細
ACT Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Materials opportunity
ST
Fair Value from
CA$5.0768.0% 割安 内在価値ディスカウント
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.
Read full narrativeAlzChem Group AG 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €160.00 |
| 52週高値 | €190.00 |
| 52週安値 | €115.80 |
| ベータ | 0.37 |
| 1ヶ月の変化 | -11.11% |
| 3ヶ月変化 | 11.11% |
| 1年変化 | 25.79% |
| 3年間の変化 | 700.00% |
| 5年間の変化 | 545.16% |
| IPOからの変化 | 495.02% |
最新ニュース
分析記事 • May 08
Investors Shouldn't Be Too Comfortable With AlzChem Group's (ETR:ACT) Earnings
Despite announcing strong earnings, AlzChem Group AG's ( ETR:ACT ) stock was sluggish. Our analysis uncovered some...
ナラティブ更新 • May 01
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.
ナラティブ更新 • Apr 17
ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.Recent updates
分析記事 • May 08
Investors Shouldn't Be Too Comfortable With AlzChem Group's (ETR:ACT) Earnings
Despite announcing strong earnings, AlzChem Group AG's ( ETR:ACT ) stock was sluggish. Our analysis uncovered some...ナラティブ更新 • May 01
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.ナラティブ更新 • Apr 17
ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.ナラティブ更新 • Apr 03
ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential
The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.
ナラティブ更新 • Mar 20
ACT: Specialty Chemicals Platform And 2026 Expansion Plans Will Support Upside
Analysts have lifted the implied fair value estimate for AlzChem Group to about €185 from roughly €177, supported by higher Street price targets in the €195 to €197 range and confidence in the company's specialty chemicals focus and production platform. Analyst Commentary Recent research updates point to a constructive tone from bullish analysts, who see the higher price targets as aligned with confidence in AlzChem Group's business model and execution around specialty chemicals.ナラティブ更新 • Mar 06
ACT: Specialty Chemicals Moat And 2026 Projects Will Drive Future Upside
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved from €185 to €195, with analysts highlighting the company's specialty chemicals performance, unique production platform and high margin growth projects as key factors in their updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on AlzChem Group, pointing to recent research updates as support for higher valuation expectations and confidence in the company’s execution.ナラティブ更新 • Feb 19
ACT: New Creatine Capacity Plan Will Support Measured Long Term Upside Potential
Analysts are holding their price target for AlzChem Group steady at €165.00. They explain the unchanged view by pointing to updated assumptions that combine a slightly higher discount rate and P/E multiple with adjusted revenue growth and profit margin expectations.ナラティブ更新 • Feb 05
ACT: New Creatine Investment Program Will Support Long Term Upside Potential
Analysts have lifted their price target on AlzChem Group from €150.00 to €165.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple in their models. What's in the News AlzChem Group AG has approved an investment program of around €120 million aimed at supporting additional profitable growth and reinforcing its presence in specialty chemicals for sports, food, and health (company announcement).分析記事 • Jan 23
Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?
Key Insights AlzChem Group's estimated fair value is €231 based on 2 Stage Free Cash Flow to Equity Current share price...ナラティブ更新 • Jan 21
ACT: New Creatine Plant And 2025 Outlook Will Underpin Balanced Prospects
Analysts have modestly trimmed their price target for AlzChem Group to €176.94 from €179.93 as minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations feed into a slightly lower fair value estimate. What's in the News AlzChem Group AG approved an investment program of around €120 million to build a more automated production plant for creatine and its precursors, along with related infrastructure, targeting additional growth in sports, food and health (Key Developments).ナラティブ更新 • Jan 07
ACT: New Creatine Capacity Expansion And 2025 Record Outlook Will Support Upside
Analysts now set a higher fair value target for AlzChem Group at €179.93 compared with €167.10 previously. They point to updated assumptions for revenue growth, profit margins and a lower future P/E multiple.ナラティブ更新 • Dec 16
ACT: New Creatine Capacity And Partnerships Will Support Balanced Long Term Outlook
Analysts have raised their price target for AlzChem Group from €97.00 to €150.00, citing slightly stronger expectations for long term revenue growth and a higher justified future P E multiple, despite a modestly lower profit margin outlook. What's in the News AlzChem Group has approved an approximately EUR 120 million investment program to build a more automated creatine production plant and related infrastructure, targeting additional annual sales in the early triple-digit million euro range.ナラティブ更新 • Dec 02
ACT: Earnings Guidance And New Product Launch Will Drive Record Performance
Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.分析記事 • Nov 24
AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 21.1x AlzChem Group AG ( ETR:ACT ) may be sending bearish signals at the...ナラティブ更新 • Nov 18
ACT: Strong Revenue Outlook And Product Launches Will Drive Upside Momentum
Analysts have raised their price target for AlzChem Group from €163.10 to €167.10, citing improved revenue growth forecasts. These improved forecasts have offset slight adjustments in the discount rate and profit margin expectations.ナラティブ更新 • Nov 02
ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation
Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.分析記事 • Oct 13
AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate
Key Insights AlzChem Group's estimated fair value is €236 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...分析記事 • Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...ナラティブ更新 • Aug 20
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.分析記事 • Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
While AlzChem Group AG ( ETR:ACT ) might not have the largest market cap around , it received a lot of attention from a...ナラティブ更新 • Aug 06
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.分析記事 • Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 4.0% to close at €156 following the...分析記事 • Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
AlzChem Group AG ( ETR:ACT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...分析記事 • Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)
Key Insights AlzChem Group's estimated fair value is €119 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...分析記事 • May 05
What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You
Despite an already strong run, AlzChem Group AG ( ETR:ACT ) shares have been powering on, with a gain of 29% in the...分析記事 • May 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG ( ETR:ACT ) will increase its dividend from last year's comparable payment on the 13th of May to...分析記事 • May 01
Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it received a lot of attention from a substantial...分析記事 • Mar 28
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
The board of AlzChem Group AG ( ETR:ACT ) has announced that it will be paying its dividend of €1.80 on the 13th of...分析記事 • Mar 18
With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 6.3% to close at €77.80 following the...分析記事 • Mar 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG's ( ETR:ACT ) periodic dividend will be increasing on the 13th of May to €1.80, with investors...分析記事 • Feb 19
Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
With a price-to-earnings (or "P/E") ratio of 14.1x AlzChem Group AG ( ETR:ACT ) may be sending bullish signals at the...
新しいナラティブ • Feb 17
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.分析記事 • Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
AlzChem Group AG ( ETR:ACT ) just reported healthy earnings but the stock price didn't move much. Investors are...分析記事 • Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
AlzChem Group AG ( ETR:ACT ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it saw a significant share price rise of 46% in the...分析記事 • Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AlzChem Group fair value estimate is €43.94 AlzChem Group's...分析記事 • May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
AlzChem Group AG's ( ETR:ACT ) recent earnings report didn't offer any surprises, with the shares unchanged over the...分析記事 • May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
Key Insights AlzChem Group will host its Annual General Meeting on 7th of May Total pay for CEO Andreas Niedermaier...分析記事 • Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
AlzChem Group AG ( ETR:ACT ) has announced that it will be increasing its dividend from last year's comparable payment...分析記事 • Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
The board of AlzChem Group AG ( ETR:ACT ) has announced that it will be paying its dividend of €1.20 on the 10th of...分析記事 • Mar 07
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
AlzChem Group AG ( ETR:ACT ) shareholders would be excited to see that the share price has had a great month, posting a...株主還元
| ACT | DE Chemicals | DE 市場 | |
|---|---|---|---|
| 7D | -3.6% | -3.9% | -0.02% |
| 1Y | 25.8% | 2.2% | 0.1% |
業界別リターン: ACT過去 1 年間で2.2 % の収益を上げたGerman Chemicals業界を上回りました。
リターン対市場: ACT過去 1 年間で0.1 % の収益を上げたGerman市場を上回りました。
価格変動
| ACT volatility | |
|---|---|
| ACT Average Weekly Movement | 6.2% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.6% |
安定した株価: ACT 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ACTの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1908 | 1,680 | Andreas Niedermaier | www.alzchem.com |
アルツケムグループAGは、その子会社とともに、ドイツ、欧州連合、欧州以外の地域、アジア、NAFTA地域、および国際的に、さまざまな化学特殊製品の開発、生産、販売を行っている。同社は3つのセグメントで事業を展開している：特殊化学品事業、基礎・中間体事業、その他・持株事業である。特殊化学品部門は、化学、食品、飼料、防衛技術、再生可能エネルギー産業で使用される特殊化学品を販売している。このセグメントでは、複合材料や接着剤、セラミック用窒化ケイ素、太陽電池モジュールなどを製造している。基礎・中間体部門は、特殊化学品原料、農業・冶金用製品、石灰、炭素、電力から製造される化学工業用中間体を製造している。また、農薬・医薬原体原料としてのグアニジン塩の製造・販売も行っている。その他・持株事業では、ケミカルパークの運営・管理サービス、各種インフラサービスの製造・販売を行っている。農業分野では「CALCIUM CYANAMIDE PERLKA」、「EMINEX」、「DORMEX」、「ALZOGUR」、「SITOFEX」、「BREAK-THRU」ブランド、動物栄養分野では「CREAMINO」ブランド、人間栄養分野では「CREAPURE」、「CREAVITALIS」、「LIVADUR」、「ALIPURE」ブランド、医薬品分野では「GUANIDINE SALTS - BIOSELECT」ブランドで製品とサービスを提供している；GUANIDINSALZE -BIOSELECT」、「CYANAMIDE」、「DICYANDIAMIDE」、「GUANAMINE」、「NITRILES」、「MELFLOCK」、「ALZOFIX」、「THIOUREA」、「NITROGUANIDINE」ブランドのファインケミカル部門、「CAD」、「CALCIPRO」、「CALZOT」ブランドの冶金部門、「テクニカルガス」、「炭化カルシウム」、「DYHARD」、「SILZOT」ブランドの再生可能エネルギー部門、受託微粉化や製造などのカスタム合成部門。同社は1908年に設立され、ドイツのトロストベルクに本社を置いている。
AlzChem Group AG 基礎のまとめ
| ACT 基礎統計学 | |
|---|---|
| 時価総額 | €1.64b |
| 収益（TTM） | €66.82m |
| 売上高(TTM) | €581.10m |
24.2x
PER（株価収益率2.8x
P/SレシオACT は割高か？
公正価値と評価分析を参照収益と収入
| ACT 損益計算書（TTM） | |
|---|---|
| 収益 | €581.10m |
| 売上原価 | €195.25m |
| 売上総利益 | €385.85m |
| その他の費用 | €319.03m |
| 収益 | €66.82m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 30, 2026
| 一株当たり利益（EPS） | 6.60 |
| グロス・マージン | 66.40% |
| 純利益率 | 11.50% |
| 有利子負債／自己資本比率 | 14.3% |
ACT の長期的なパフォーマンスは？
過去の実績と比較を見る| AlzChem Group 配当日 | |
|---|---|
| 配当落ち日 | May 06 2026 |
| 配当支払日 | May 08 2026 |
| 配当落ちまでの日数 | 4 days |
| 配当支払日までの日数 | 2 days |
ACT 配当は確実ですか？
ACT 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/08 09:59 |
| 終値 | 2026/05/08 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AlzChem Group AG 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Konstantin Wiechert | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Gerhard Orgonas | Berenberg |